 BioVie Inc NASDAQ:BIVI has announced positive results from two Phase 2 trials assessing NE3107s potential in Parkinsons Disease PD and Alzheimers Disease AD. The NM201 study NCT05083260 is a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in Parkinsons disease PD participants treated with carbidopalevodopa and NE3107. 